Calliditas Therapeutics   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Stockholm Sweden (2004)

Organization Overview

First Clinical Trial
2004
NCT00160082
First Marketed Drug
2021
budesonide (rhinocort)
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

CALLIDITAS | Calliditas Therapeutics AB | Pharmalink | Pharmalink AB | Pharmalink AB, Stockholm, Sweden | Pharmalink International Ltd.